Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Descending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00378-7133-93 00378-7133 erlotinib hydrochloride Erlotinib Hydrochloride 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 Nov. 30, 2022 No Longer Used
46708-0567-30 46708-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
46708-0567-90 46708-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
78206-0147-01 78206-0147 trastuzumab Ontruzant 150.0 mg/1 Immunotherapy Monoclonal Antibody HER2 Intravenous June 1, 2021 In Use
82454-0212-03 82454-0212 Nilutamide Nilutamide 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Nov. 22, 2019 In Use
00378-9045-01 00378-9045 Cysteamine bitartrate Cystagon 150.0 mg/1 Chemotherapy Cystine-Depleting Agent Oral Aug. 15, 1994 Sept. 4, 2018 In Use
00378-9045-05 00378-9045 Cysteamine bitartrate Cystagon 150.0 mg/1 Chemotherapy Cystine-Depleting Agent Oral April 11, 2005 In Use
00078-0709-56 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00078-0709-94 00078-0709 Capmatinib TABRECTA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor MET Oral May 6, 2020 In Use
00597-0145-60 00597-0145 Nintedanib Ofev 150.0 mg/1, 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Oral Oct. 17, 2014 In Use

Found 10,000 results in 11 milliseconds — Export these results